{"entity":{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","aka":[],"tldr":"Avenzo in-licenses Chinese assets, including the Nectin-4×TROP2 bispecific ADC AVZO-103 and a CDK2 inhibitor, and agreed in May 2026 to go public by merging with Rallybio.","summary":"Avenzo Therapeutics, based in San Diego, in-licenses Chinese oncology assets for Western development, including the Nectin-4 by TROP2 bispecific antibody-drug conjugate AVZO-103 and a CDK2 inhibitor. Its pipeline comprises AVZO-103, AVZO-021, the CDK2 inhibitor, and AVZO-1418, an EGFR by HER3 ADC. On 31 May 2026 Avenzo agreed to merge with Rallybio, a Nasdaq-listed company, alongside a 215 million dollar private placement; when the merger completes, Rallybio is to be renamed Avenzo Therapeutics and trade under the symbol AVZO, and on 29 October 2026 the merger had not yet closed. OnCo links it to Nectin-4 and TROP2 as targets and to the bispecific ADC technology. Whether a company that licenses rather than discovers can differentiate in a crowded bispecific ADC field is the open question. The bispecific ADC page carries the wider context.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.avenzotx.com"},{"label":"Rallybio and Avenzo merger agreement (SEC 8-K, June 2026)","url":"https://www.sec.gov/Archives/edgar/data/1739410/000119312526249790/d19106d8k.htm"},{"label":"Merger cash distribution update (SEC 8-K, October 2026)","url":"https://www.sec.gov/Archives/edgar/data/1739410/000119312526432114/d353286d8k.htm"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","targeted-therapy"],"technologies":[],"targets":["nectin4","trop2"],"drugs":["avzo-021","avzo-023"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05867251","nct07193511","nct07038343"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Freshened 29 October 2026 from Avenzo's newsroom and Rallybio's SEC filings (merger agreement 8-K, S-4 prospectus of 15 October 2026 and an 8-K of 26 October 2026). The merger and the expected Nasdaq listing as AVZO were pending at the time of writing; the post-merger ownership split was not recorded here. Avenzo's own newsroom also lists a 60 million dollar Series B in September 2025, not added as a funding row because the release itself was not read."],"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.avenzotx.com","investors":[],"funding":[]},"route":"/companies/avenzo/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"avzo-021","kind":"drug","name":"AVZO-021","route":"/drugs/avzo-021/"},{"id":"avzo-023","kind":"drug","name":"AVZO-023","route":"/drugs/avzo-023/"}],"trial":[{"id":"nct07038343","kind":"trial","name":"AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)","route":"/trials/nct07038343/"},{"id":"nct07193511","kind":"trial","name":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","route":"/trials/nct07193511/"},{"id":"nct06998407","kind":"trial","name":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","route":"/trials/nct06998407/"},{"id":"nct05867251","kind":"trial","name":"Study of AVZO-021 in Patients With Advanced Solid Tumors","route":"/trials/nct05867251/"}],"technology":[{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"}],"company":[{"id":"sr-one","kind":"company","name":"SR One","route":"/companies/sr-one/"}]}}